Stocks · News reference
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients with elevated cardiovascular risk and systemic inflammation. Topline data is anticipated in the second half of 2026. The company also announced participation in three upcoming investor conferences in September 2026.
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60) per share from the
BioAge Labs announced the first participant dosing in QUELL-CV, a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor for patients with obesity and elevated inflammation. Phase 1 data showed BGE-102 achieved up to 98% suppression of IL-1β and 86% median hsCRP reductions. The company also plans to initiate QUELL-DME trial in diabetic macular edema in mid-2026. BioAge reported Q2 2026 net loss of $26.1 million with $381.3 million in cash, sufficient to fund operations through 2029.
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share
Filed: 2026-08-14 AccNo: 0001193125-26-350349 Size: 345 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits